Academic Journal
AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
| العنوان: | AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization |
|---|---|
| المؤلفون: | Azzalini E., Tierno D., Bartoletti M., Barbazza R., Giorda G., Puglisi F., Cecere S. C., Losito N. S., Russo D., Stanta G., Canzonieri V., Bonin S. |
| المساهمون: | Azzalini, E., Tierno, D., Bartoletti, M., Barbazza, R., Giorda, G., Puglisi, F., Cecere, S. C., Losito, N. S., Russo, D., Stanta, G., Canzonieri, V., Bonin, S. |
| سنة النشر: | 2022 |
| المجموعة: | Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) |
| مصطلحات موضوعية: | HGSOC, AKT1, AKT2, AKT3, SET, classic, surrogate marker, BRCA statu, homologous recombination status |
| الوصف: | High-grade serous ovarian cancer (HGSOC) is among the deadliest gynecological malignancies. The acquired resistance to platinum-based therapies and the intrinsic heterogeneity of the disease contribute to the low survival rate. To improve patients’ outcomes, new combinatorial approaches able to target different tumor vulnerabilities and enhance the efficacy of the current therapies are required. AKT inhibitors are promising antineoplastic agents able to act in synergy with PARP inhibitors, but the spectrum of patients who can benefit from this combination is unclear, since the role of the three different isoforms of AKT is still unknown. Here, we study the expression of AKT isoforms on a retrospective cohort of archive tissue by RT-droplet digital PCR (ddPCR) analyzing their association with the clinicopathological features of patients. Based on AKT1/AKT2 and AKT1/AKT3 ratios, we define four AKT classes which were related to patients’ survival, tumor morphology and BRCA1 expression. Moreover, our results show that high AKT3 expression levels were frequently associated with tumors having classic features, a low number of mitoses and the presence of psammoma bodies. Overall, our study obtains new insights on AKT isoforms and their associations with the clinicopathological features of HGSOC patients. These evidences could help to better define the subsets of patients who can benefit from AKT and PARP inhibitors therapy in future clinical trials. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/35053468; info:eu-repo/semantics/altIdentifier/wos/WOS:000758577000001; volume:14; issue:2; firstpage:"-"; lastpage:"-"; numberofpages:15; journal:CANCERS; info:eu-repo/grantAgreement/EC/H2020/667403; http://hdl.handle.net/11368/3007040; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85122363145; https://www.mdpi.com/2072-6694/14/2/304; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773580/ |
| DOI: | 10.3390/cancers14020304 |
| الاتاحة: | http://hdl.handle.net/11368/3007040 https://doi.org/10.3390/cancers14020304 https://www.mdpi.com/2072-6694/14/2/304 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773580/ |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.86E3AD37 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers14020304 |
|---|